BIA Med
Bia Med is a Baby-Tech & Fem-Tech health startup developing innovative breast monitoring technology – a "Smart Bra" – that will provide women with personalized feedback on key physiological changes in their breasts.
Epivision Genetics
Epivision has developed a breakthrough, epigenetic liquid biopsy platform that enables precise disease detection at the earliest stages. Epivision promises to improve early detection, diagnosis, and monitoring of multiple cancer types.
Chiral Energy
Controlling electron spin to significantly improve Batteries, Electrolyzers and Fuel cells
Nuri Braintech
Nuri Braintech is ushering in a new era of precision psychiatry with a breakthrough therapeutic solution to restore lives for millions of patients living with post-traumatic stress disorder (PTSD) and other intractable conditions.
EcoCrystal
EcoCrystal develops innovative, nature inspired, reflective colorants for the food, cosmetics, personal care and pharmaceutical industries.
Metabocure
MetaboCure is dedicated to developing innovative biopharmaceutical solutions for cancer cachexia and other metabolic disorders.
Sub-Q Bionics Secures Exclusive Worldwide Rights to Use of Implantable Technology for Absorbing Lymphatic Fluid in Lymphedema Patients
Sub-Q Bionics, a Medtech company developing the world’s first fully implantable bionic lymphatic drainage system, announces that it has signed a licensing agreement with Yeda Research and Development Company, Ltd., the commercial arm of the Weizmann Institute, and Health Corporation next to Shamir Medical Center (Assaf Harofeh) (R.A.) , and now possesses rights to a key mechanical component essential in the design of Sub-Q Bionics’ fully implantable drainage system. The technology was invented by Prof. Brian Berkowitz and Prof.
Cellyrix Therapeutics
Cellyrix is pioneering a new paradigm in cancer treatment by leveraging single-cell RNA sequencing and AI to unravel the complexities of tumor heterogeneity.
Larkspur Biosciences
Targeting enzymes that control cancer cell state and fitness make cancer cells susceptible to intrinsic and immune-mediated killing but drugging these pathways has been limited by poor tractability.
Pages
